1. Scrip
  2. >>Business
  3. >>Strategy

Kite CEO Christi Shaw On How Gilead Plans To Stay On Top In Cell Therapy

 
• By Joseph Haas

Shaw cites manufacturing speed and success as competitive edges. The Gilead subsidiary unveiled data at ASCO positioning Tecartus, its second CAR-T therapy, to add B-cell acute lymphoblastic leukemia to label.

3d illustration of T cells attacking a cancer cell
Manufacturing is key to Kite's cell therapy success, CEO Shaw says

Kite Pharma, Inc. CEO Christi Shaw is optimistic about Gilead Sciences, Inc.maintaining a leadership position in cancer cell therapy, especially as its second CAR-T therapy Tecartus appears poised for expansion in B-cell acute lymphoblastic leukemia. In an interview with Scrip, Shaw highlighted data recently presented at the American Society of Clinical Oncology annual meeting as evidence of the Kite subsidiary's expansion and commitment to cell therapy.

The company’s announcement of an alliance with Shoreline Biosciences, Inc. on 18 June, after the interview, on chimeric antigen receptor natural killer cell therapies (CAR NK) and targeted macrophages is evidence of how aggressive Kite and Gilead are being about staying on the cutting edge of the field with allogeneic off-the-shelf, standardized cell therapy. The partnership, worth up to $2

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

More from Business

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By Andy Smith

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.